| Cas No.: | 954126-98-8 |
| Synonyms: | Danirixin,GSK 1325756,GSK1325756,GSK-1325756 |
| SMILES: | CC1=C(C=CC=C1F)NC(=O)NC2=C(C(=C(C=C2)Cl)S(=O)(=O)[C@H]3CCCNC3)O |
| Formula: | C19H21ClFN3O4S |
| M.Wt: | 441.9 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Danirixin is a selective, and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8. |
| Target: | CXCL8-CXCR2:12.5 nM (IC50) |
| In Vitro: | Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine[1]. |
| References: | [1]. Miller BE, et al. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist?--in healthy adult subjects. BMC Pharmacol Toxicol. 2015 Jun 20;16:18. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|